Zurich (Reuters) – Roche announced Tuesday its intention to initiate $ 50 billion (43.31 billion euros) in the United States over the next five years, one of the largest investment measures taken by a company in response to President Donald Trump’s customs policy.
The Swiss pharmaceutical giant clarified that this investment would create more than 12,000 jobs, including nearly 6,500 in the construction sector, as well as 1,000 in new facilities or enlarged sites.
This announcement comes after Novartis, another Swiss drug manufacturer, announced earlier this month investing $ 23 billion in the United States to enlarge its existing facilities and build new ones.
Roche clarified that its investment plan will include new research and development sites as well as expanded production facilities in Indiana, Pennsylvania, Massachusetts and California.
Once the new production capacity has been put into service, the group plans to export more drugs from the United States than it is important.
The director general of Roche, Thomas Schinecker, said that this investment underlined the group’s commitment to the United States.
“Our $ 50 billion investments over the next five years will lay the foundations for our next era of innovation and growth, for the benefit of American and world patients,” he said in a statement.
(Written, Noémie Naudin, edited by Augustin Turpin)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
